Generic Name and Formulations:
Interferon beta-1b 0.3mg; per vial; pwd for SC inj after reconstitution; contains albumin (human), mannitol; preservative-free.
Indications for BETASERON:
To reduce the frequency of clinical exacerbations of relapsing forms of multiple sclerosis (MS) in patients who have experienced a first clinical episode and have MRI features consistent with MS.
Pre-medicate with analgesics and/or antipyretics on treatment days to ameliorate flu-like symptoms. May be administered by syringe and needle or Betaconnect autoinjector. ≥18yrs: initially 0.0625mg (0.25mL) SC every other day; increase by 25% every 2 weeks to target dose of 0.25mg (1mL) SC every other day.
<18yrs: not established.
Monitor for signs/symptoms of hepatic injury; consider discontinuing if elevated transaminase levels or jaundice occurs. Depression. Suicidal ideation. Pre-existing CHF: monitor for worsening cardiac function at initiation and during treatment. Risk of thrombotic microangiopathy, drug-induced lupus erythematosus; discontinue if occurs. Myelosuppression. Monitor CBCs, differential, platelets, blood chemistries; liver function (at 1, 3, and 6 months then periodically). Pregnancy (Cat.C; may be abortifacient). Nursing mothers: not recommended.
Risk of hepatic injury with concomitant hepatotoxic drugs or alcohol.
Inj site reactions, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, asthenia; inj site necrosis (suspend therapy if multiple lesions occur); rare: hepatic injury, anaphylaxis, possible seizures.
Single-use vials (w. prefilled diluent syringe, supplies)—5, 14
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|